Archive · 2026 · September 2026

Daily digest — 2026-09-16

2026-09-16

Today's digest covers 8 science and 5 business items: a strong showing for targeted protein degradation and AI-guided computational screening, plus new GPCR and covalent-chemoproteomics targets, alongside three major trial readouts including ivonescimab's rare survival win over Keytruda.

⚗️

Medicinal Chemistry

6 articles

First-in-Class Molecular Glue Selectively Degrades Spliceosome Protein WBP4 via CRBN

  • Discovered dWBP4-1 through proteomic profiling of a CRBN-binding compound library, followed by SAR optimization.
  • Acts as a molecular glue, forming a CRBN ternary complex via a canonical G-loop-mediated interaction to recruit WBP4 (WW domain-binding protein 4), a spliceosome-associated scaffold protein.
  • Degradation is rapid and occurs at nanomolar concentrations.
  • Selectivity across the proteome is reported as high, with minimal downstream transcriptomic or alternative-splicing effects observed elsewhere.
  • Mapped a minimal ~41-residue WBP4 degron sequence and used it to build "wTAG," a fusion-tag degradation platform.
  • wTAG enables monotonic, dose-dependent degradation without the hook effect seen in some bifunctional degraders.
💡 Points

A canonical G-loop-mediated ternary complex — reassuring, not exotic: this is the same validated CRBN surface, not a new liability profile to characterize from scratch. The compact ~41-residue degron is the real tell for tractability — that's a defined element, not a diffuse IDR, so SAR here should be rational rather than lucky. Nanomolar potency with reported high proteome-wide selectivity is the headline number, though for a spliceosome-associated protein I'd want orthogonal splicing/transcriptomic data before fully trusting "minimal downstream effects." The piece I'd actually chase into my own work is wTAG: a monovalent, hook-effect-free degron tag beats dTAG-style bifunctional systems for clean dose-response in target-validation studies, regardless of whether WBP4 itself ever becomes a drug target.

Selective and Potent First-in-Class CRBN-Dependent Molecular Glue Degraders of WW Domain-Binding Protein 4 ↗

Cyclic Peptide PROTACs Knock Down HIF-1α — Until Hypoxia Outpaces Them

  • Custom bifunctional amino acids — carrying a VHL-recruiting ligand and a variable linker — are incorporated directly during solid-phase peptide synthesis, an alternative to conventional PEG-based linkers for building cyclic peptide degraders.
  • A SICLOPPS-derived cyclic peptide HIF-1 inhibitor serves as the warhead, yielding cyclic peptide PROTACs (CP-PROTACs) that engage VHL in a productive ternary complex.
  • The degraders lower HIF-1α levels and hypoxia-response signaling across multiple cancer cell lines.
  • Degradation is oxygen-state dependent — robust under moderate hypoxia but largely lost under more severe hypoxia, even though the degrader still engages and marks HIF-1α there.
  • The activity loss reflects a kinetic mismatch, not a binding failure: HIF-1α resynthesis outpaces degradation, pointing to a general ceiling on PROTAC efficacy against rapidly replenished targets.
💡 Points

Smart move folding the VHL ligand and linker into a bifunctional amino acid for direct SPPS incorporation — that sidesteps the PEGylation/conjugation bottleneck that makes cyclic peptide degraders such a pain to iterate on, and it turns linker SAR into a synthesis-cycle variable instead of a separate coupling step. The SICLOPPS-derived warhead is a nice proof that a cyclic peptide can grip a transcription-factor surface a small molecule can't easily touch, so on chemotype comparison this favors the peptide side. But the real flag for my own work is the hypoxia dropout: ternary complex still forms, HIF-1α still gets marked, degradation just can't keep up. That's not a binding problem I'd fix by optimizing the VHL warhead — it's a turnover-rate problem, and it says something uncomfortable about any PROTAC campaign against a target with fast resynthesis kinetics.

Cyclic Peptide PROTACs Restore VHL-Mediated HIF-1α Degradation in Hypoxia ↗

Machine-Learning Screen of 5M Candidates Yields Light-Activated PARP1 Inhibitors

  • Combined protein–ligand docking, ML force fields, quantum chemistry, and free-energy perturbation (FEP) to screen roughly 5 million hypothetical photoactive PARP1 ligands.
  • Docking identified candidates with differential PARP1 binding between light-exposed and dark states; ML force fields and QM calculations predicted pKa, absorption spectra, and thermal half-lives, while graph-based surrogate models screened the remaining library.
  • Excited-state nonadiabatic dynamics simulations (with ML force fields) estimated photoswitching quantum yields; FEP refined binding-affinity predictions for top hits.
  • Prioritized a small set of synthetically accessible candidates combining red-shifted absorption (favoring deeper tissue penetration), therapeutically suitable thermal half-lives, and light/dark-selective PARP1 binding.
  • Predictions were experimentally validated, demonstrating an end-to-end computational-to-experimental pipeline for designing light-activated (photopharmacological) cancer therapeutics.
💡 Points

Five million virtual candidates funneled down to a handful that actually work is the real story — that pipeline (docking → ML force fields → QM → nonadiabatic dynamics → FEP) is doing what a med chem team's SAR intuition used to do by hand, just faster and across chemical space no bench chemist would ever hand-explore. The binding-mode hypothesis is straightforward: a photoswitch appended to (presumably) a nicotinamide-mimetic PARP1 pharmacophore toggles pocket occupancy between light and dark isomers, so "selectivity" here means spatiotemporal control over tumor tissue, not isoform selectivity against PARP2/tankyrases — a different axis entirely from what olaparib or niraparib were ever optimized for. Red-shifted absorption for tissue penetration plus a therapeutically workable thermal half-life are the tractability bottlenecks that usually kill photopharmacology leads, so getting synthetically accessible hits past both, and into validated wet-lab data, is the genuinely notable part.

Computational Design and Experimental Validation of Photoactive PARP1 Inhibitors ↗

Covalent Metal-Complex Platform Maps Proteome-Wide Cysteines, Nets a PRMT1 Inhibitor

  • Introduces reactive metallo-scaffolds (r-mS), a new class of covalent metal complexes bearing a chloroacetamide electrophile designed to engage ligandable cysteines across the proteome.
  • Chemoproteomic profiling of a focused r-mS series in HEK293T cell lysate mapped novel cysteine engagement proteome-wide.
  • Metal identity, arene substituents, and overall scaffold topography together tune cysteine reactivity and targeting selectivity.
  • Lead compound r-mS-2 engages a cysteine within the functionally relevant SAM-binding domain of the methyltransferase PRMT1, confirmed by intact-protein LC-MS.
  • That engagement functionally inhibits PRMT1 activity, tying a covalent hit directly to modulation of a validated target.
  • Positions the platform as a generalizable route to target discovery for rational, next-generation metallodrug design.
💡 Points

The SAM-pocket cysteine hit on PRMT1 is the part I trust most here — that's a genuinely druggable site, and confirming occupancy by intact-protein LC-MS rather than an activity readout alone is the right bar. Where I'd slow down is selectivity: tuning reactivity through metal identity and arene substituents is a real lever, but it's one more variable than iodoacetamide/chloroacetamide fragment libraries already juggle, and a lysate screen doesn't tell me the off-target cysteine load in cells. Chemically, this is genuinely unfamiliar ground for most of us — ligand exchange, redox lability, and batch-to-batch reproducibility are liabilities organic warheads simply don't have. Against established cysteine-directed chemoproteomic platforms, r-mS adds an interesting third tuning axis, not yet a clear win. Metallodrugs as a class still carry that same tractability tax relative to organic small molecules — worth watching, not yet worth reaching for.

Proteome-Wide Target Identification Using Reactive Metallo-Scaffolds (r-mS): A Platform for Metallodrug Discovery ↗

Dynamic Combinatorial Chemistry Delivers a Reversible, Sub-Picomolar Trivalent Thrombin Inhibitor

  • A PNA-templated dynamic combinatorial chemistry (DCC) platform assembles a three-fragment library (~125,000 possible combinations) using DNA/PNA hybridization handles for unbiased equilibration.
  • Thrombin itself templates the library, selecting and amplifying the best-binding fragment combination; size-exclusion filtration coupled with MALDI mass spectrometry gives a full selection-to-readout cycle in under an hour.
  • The selected trivalent assembly engages thrombin's active site plus both exosites simultaneously, driving exceptionally high (sub-picomolar-range) binding affinity and near-stoichiometric inhibition.
  • Unlike covalent thrombin inhibitors, binding is fully reversible — pharmacologically relevant for an anticoagulant, where reversibility matters for managing bleeding risk.
  • Demonstrates target-templated DCC as a rapid route to multivalent, exosite-spanning inhibitors, even against a well-studied target.
💡 Points

Sub-picomolar affinity out of a 125,000-member DCC library gets my attention immediately — that's an avidity effect, not a single tight pocket, and it's essentially bivalirudin's active-site/exosite-1 logic pushed one contact further to include exosite II as well. Exosite engagement should also buy real selectivity over trypsin-like serine proteases that don't share thrombin's exosite topology, though I'd want that confirmed head-to-head against fXa and trypsin. My hesitation is tractability: a DNA/PNA-templated trivalent assembly is a fantastic proof-of-concept and chemical tool, not yet a lead — that's a long way from oral. Against DOACs' one-pocket, small-molecule simplicity, this wins on affinity and reversibility but loses badly on drug-likeness; the real test is whether target-templated DCC can be steered toward a druggable combination, not just the tightest binder.

Discovery of a Reversible Sub-Picomolar Thrombin Inhibitor Using DCC ↗

Photocrosslinking Probes Reveal Nonhistone Partners of the TRIM24 Bromodomain

  • Genetic code expansion installed site-specific photocrosslinkers (AzF and BzF) at residue L922, within the acetyllysine-binding pocket of the TRIM24 bromodomain.
  • Both crosslinker variants retained recognition of acetylated histones and crosslinked efficiently under UV, enabling interaction-based protein profiling (IBPP) in a native context.
  • Quantitative proteomics of the two complementary probes gave differing capture profiles: AzF enriched for NPM1, BzF enriched for CDK9, with MAP4, RAN, and SND1 as additional candidates.
  • ChIP-seq showed TRIM24, CDK9, and NPM1 co-occupying regions near transcription start sites of cancer-associated genes.
  • Together the results suggest the TRIM24 bromodomain reads acetylation on nonhistone proteins as well as histones, broadening its reader function and informing chemical-probe design against this pocket.
💡 Points

The crosslinker sits inside the acetyllysine pocket itself, at L922 — that's not a fortuitous surface hit, it's evidence TRIM24 reads acetylated lysine on NPM1 and CDK9 through the same pocket it uses on histones, not a peripheral contact. That reframes TRIM24 as an acetyl-lysine reader with a broader substrate scope, and it means any inhibitor competing for that pocket is also competing off a nonhistone binding event, not just a histone mark. Practically, TRIM24 probe programs need NPM1/CDK9 engagement counter-screens now, and the TSS co-occupancy by ChIP-seq suggests that off-target isn't background noise but transcriptionally active. Worth flagging: this is GCE-based interactome mapping, not medicinal chemistry — no chemotype, no SAR, just a map of what a pocket-directed probe will also touch. BET programs learned this same lesson with nonhistone acetyl-lysine substrates years ago; TRIM24 is only now catching up to that complexity.

Mapping the Nonhistone Interactome of the TRIM24 Bromodomain Using Genetically Encoded Complementary Photocrosslinkers ↗

🧬

Pharmacology

1 article

GPR41 Agonism Curbs Endotoxemic Inflammation via Autophagy-Dependent NF-κB Suppression

  • GPR41/FFAR3, a short-chain-fatty-acid-sensing GPCR, was tested as a target for dampening gut-derived endotoxemia in a macrophage model of endotoxin stress.
  • The selective agonist AR420626 activated GPR41 and blunted downstream pro-inflammatory signaling, cutting output of nitric oxide, IL-6, MCP-1, and iNOS.
  • This anti-inflammatory effect tracked to suppression of NF-κB signaling, the central pathway driving those mediators.
  • Agonist treatment also boosted autophagic flux, marked by increased LC3-I-to-LC3-II conversion.
  • Blocking autophagy pharmacologically erased AR420626's protective effect, indicating autophagy induction is mechanistically required rather than incidental to the anti-inflammatory action.
  • Findings position GPR41 as a druggable node linking gut microbial metabolite sensing to control of systemic inflammation in metabolic endotoxemia.
💡 Points

AR420626 is doing its job as a chemical probe here, not auditioning as a drug — worth keeping that line bright. The autophagy-blockade rescue experiment is the real anchor: losing the phenotype when you knock out autophagy is exactly the epistasis data that justifies chasing GPR41 rather than filing it under "yet another anti-inflammatory hit." Selectivity is my first question mark — GPR41 sits right next to GPR43/FFAR2 in the SCFA-sensing GPCR family, sharing pocket architecture, so I'd want counter-screens before trusting any binding-mode hypothesis. Tractability-wise, class A GPCRs are historically good chemical space, but SCFA-mimetic ligands trend small and polar — solid fragment-to-lead starting points, not obviously oral-bioavailable as-is. Early hit-validation signal, not a lead series yet.

G-Protein-Coupled Receptor 41 (GPR41) as a Therapeutic Target for Metabolic Endotoxemia: Mechanistic Insights into AR420626-Induced Autophagy and Nuclear Factor kappa B (NF-κB) Suppression ↗

💻

Computational & AI

1 article

ChemBERTa-Guided Virtual Screening Identifies Repurposable CASP4 Inhibitors for Alzheimer's Disease

  • Ligand-based virtual screening pipeline mined DrugBank for CASP4 inhibitor candidates, combining docking-score prioritization with SMILES-derived ChemBERTa embeddings and physicochemical descriptors.
  • A Random Forest classifier trained on the hybrid ChemBERTa/physicochemical feature set separated active from inactive compounds with high accuracy and enriched actives among top-ranked hits.
  • A companion Random Forest regressor, trained on experimental pIC50 values, ranked candidates by predicted potency.
  • Cheminformatics filtering, PK-PD evaluation, and molecular docking narrowed the field to five DrugBank-listed candidates.
  • Molecular dynamics simulations and MM/PBSA free-energy analysis confirmed stable binding poses for the top candidates.
  • Positions the workflow as a drug-repositioning route toward CASP4-targeted Alzheimer's disease therapy, a caspase linked to neuroinflammation and pyroptosis.
💡 Points

What actually sells this to me is the DrugBank sourcing, not the screening funnel itself: the five candidates that survive docking, ChemBERTa/RF classification, and MM/PBSA already come with known ADMET and need no de novo synthesis to reach an animal model — that's a tractability shortcut a genuine hit-finding campaign rarely gets. CASP4's pocket is the usual caspase catalytic Cys-His dyad, so the real question the MD trajectories should answer is whether these scaffolds actually engage that dyad or just sit in a peripheral exosite; binding energy alone won't tell me that. Selectivity is the open flag — caspase-1/3/4 share fold homology, and off-target caspase hits in a neuroinflammation context could cut the wrong way. Methodologically, ChemBERTa embeddings layered onto classical descriptors for RF triage is a sane upgrade over pure docking-score ranking, though I'd want held-out chemotype validation before trusting the pIC50 regressor outside its training distribution.

AI Accelerated Chemical Screening Integrates ChemBERTa to Identify Repositionable CASP4 Inhibitors via MD Simulations and MM/PBSA Analysis ↗

🏢

Industry News

5 articles

Vera's TRUTAKNA Meets All Endpoints in Final ORIGIN 3 Kidney Disease Trial

  • Vera Therapeutics reported that TRUTAKNA (atacicept) met all prespecified endpoints in the final, two-year efficacy analysis of the Phase 3 ORIGIN 3 trial in adults with primary IgA nephropathy (IgAN), a chronic autoimmune kidney disease.
  • Atacicept is a BAFF/APRIL-targeting fusion protein; treatment stabilized kidney function and reduced the risk of kidney-related death and other disease complications.
  • Statistically significant, hierarchically tested reductions were achieved across proteinuria, galactose-deficient IgA1 (Gd-IgA1) levels, and hematuria.
  • eGFR trends aligned with the KDIGO clinical treatment goal of slowing kidney-function decline toward the normal physiologic rate.
  • TRUTAKNA already holds FDA accelerated approval for IgAN, granted July 2026; these final two-year data are intended to support Vera's case for full, non-accelerated approval.
💡 Points

Full, hierarchically-tested endpoint clearance across proteinuria, Gd-IgA1, and hematuria is exactly the kind of data package payers and prescribers weight most heavily when a drug's approval is still accelerated and provisional — this reads as Vera's strongest case yet for converting TRUTAKNA to full approval and retiring the confirmatory-trial overhang that's been sitting on the stock. That matters disproportionately for a single-asset company: Vera has no second program to fall back on if ORIGIN 3 had disappointed, so a clean conversion is existential, not incremental. It also sharpens the IgAN scramble — Travere's sparsentan (Filspari), Novartis's atrasentan (Vanrafia), and Otsuka's entrants are all fighting for first-line real estate in a field that's gone from orphan afterthought to genuinely contested in under two years. Durable, un-caveated data is now the differentiator, not novelty of mechanism alone.

Vera kidney drug Trutakna shows strong final results in Phase 3 trial ↗

BioNTech/OncoC4's Gotistobart Nearly Doubles Survival in Hard-to-Treat Lung Cancer Ahead of Pivotal Readout

  • BioNTech and OncoC4 reported stage 1 overall-survival data from the phase 3 PRESERVE-003 trial in metastatic squamous NSCLC, ahead of the pivotal stage 2 readout.
  • Gotistobart (BNT316/ONC-392) is a pH-sensitive anti-CTLA-4 antibody designed to selectively deplete regulatory T cells in the tumor microenvironment, a differentiated mechanism versus conventional CTLA-4 blockers like ipilimumab.
  • In 87 randomized patients who had progressed on prior PD-(L)1 and platinum chemotherapy, median overall survival nearly doubled: 18.5 months with gotistobart versus 10.0 months with docetaxel (HR 0.56).
  • Grade ≥3 treatment-related adverse events were similar between arms (44.4% vs 48.8%), with a manageable safety profile.
  • Pivotal stage 2, with overall survival as the primary endpoint, is now underway at 160+ global sites.
💡 Points

The differentiator here is mechanism, not just efficacy: a pH-selective, tumor-restricted Treg-depletion approach delivering a near-doubling of OS over docetaxel with grade ≥3 toxicity roughly flat to chemo is the tolerability profile ipilimumab-based regimens have never cleared — that's the real competitive wedge against BMS's checkpoint franchise and every less-selective CTLA-4 follower. Eighty-seven patients and an HR of 0.56 is directional, not confirmatory, but it's a strong enough signal in a chemo-refractory population with no compelling 2L+ standard to justify running 160+ sites into stage 2 ahead of topline data. Bigger picture: this is BioNTech executing its post-COVID pivot — building a wholly-owned, mechanistically differentiated oncology franchise rather than leaning on mRNA vaccine partnerships. A pivotal win makes gotistobart the company's first major non-mRNA solid-tumor asset with real blockbuster optionality.

BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout ↗

Ivonescimab Beats Keytruda on Survival in Phase 3 NSCLC Trial

  • Ivonescimab (Akeso/Summit's PD-1 x VEGF bispecific) reduced risk of death by 27% vs. Merck's Keytruda in the Phase 3 HARMONi-2 trial.
  • Trial enrolled treatment-naive, PD-L1-positive advanced NSCLC patients in China.
  • Median overall survival: 30.75 months for ivonescimab vs. 22.57 months for Keytruda.
  • Adds to the trial's earlier primary PFS win — a 49% reduction in progression/death risk (11.14 vs. 5.82 months).
  • Fourth Phase 3 ivonescimab readout to hit its OS endpoint, bolstering the case for combining PD-1 blockade with anti-VEGF activity in one bispecific.
  • Akeso (China) and Summit Therapeutics (ex-China licensee) are co-developing the drug as a head-to-head Keytruda challenger.
💡 Points

A head-to-head overall-survival win over Keytruda is about as rare an event as oncology drug development produces — Merck's franchise has fended off nearly every direct challenger for a decade, and ivonescimab is now four-for-four on OS across its Phase 3 program. That changes the calculus for Summit, whose ex-China license from Akeso looked speculative at signing and now looks like one of the shrewder biotech deals in recent memory — every data cut adds leverage for future pricing, partnering, or M&A conversations. It's also the clearest advertisement yet for the China-originated-asset licensing wave Western biotechs have been chasing: a domestically-developed bispecific outrunning the world's best-selling drug in its own trial. For Merck, it lands squarely as Keytruda nears patent cliff — this isn't a niche subtype win, it's a direct share threat in frontline NSCLC, the franchise's core indication.

Akeso details survival win for its PD-1xVEGF drug versus Keytruda ↗

BridgeBio Oncology Narrows BBO-8520 Focus to 2L+ NSCLC Plus Pembrolizumab

  • BridgeBio Oncology Therapeutics narrowed the development scope of its lead ON/OFF-state KRAS inhibitor BBO-8520, focusing specifically on second-line-plus (2L+) NSCLC in combination with checkpoint inhibitor pembrolizumab, trimming a broader earlier-stage development plan.
  • The move follows new data showing a strong objective response rate for the combination in patients whose lung cancer had already progressed on a prior KRAS G12C inhibitor, with a somewhat lower but still meaningful response rate across all doses tested.
  • BBO-8520 holds FDA Fast Track designation for previously treated, KRAS G12C-mutated metastatic NSCLC.
  • The company still runs two other Phase 1 KRAS-pathway programs: BBO-11818, a pan-KRAS (ON/OFF) inhibitor with Fast Track designation in pancreatic ductal adenocarcinoma, and BBO-10203, a RAS-PI3Kα interaction inhibitor enrolling the multi-tumor BREAKER-101 basket trial.
  • The narrowing reads as a deliberate focusing of resources on the most differentiated combination signal, not a full retreat from the asset.
💡 Points

BBO-8520 sits in a brutal field — Amgen's sotorasib, Mirati/BMS's adagrasib, and Revolution Medicines' RAS(ON) inhibitors are all fishing in the same post-G12C-progression pool, so a strong response signal there is worth more to BridgeBio than thin coverage spread across earlier lines. Narrowing scope rather than killing the asset outright reads as capital discipline: in a funding environment that punishes diffuse spend, concentrating trial resources on the combination with the clearest data is the rational move, not a retreat. The two other KRAS programs (BBO-11818, BBO-10203) staying active confirms the platform bet is intact — this is portfolio triage, not a pipeline unraveling. Read the stock dip as the market's reflexive reaction to the word "narrows," not a verdict on the science; this is strategic analysis, not investment advice.

BridgeBio Oncology slides as it tightens the scope of its KRAS program ↗

Merck KGaA's EMD Serono Acquires Two of PostEra's Oral Fertility Drug Programs

  • EMD Serono, Merck KGaA's US/Canada healthcare business, acquired two fertility-focused small-molecule drug discovery programs from AI-driven biotech PostEra for an undisclosed sum described as "mid-double-digit millions."
  • The deal covers an oral FSHR (follicle-stimulating hormone receptor) agonist for ovarian stimulation in IVF, and an oral LHCGR (luteinizing hormone/choriogonadotropin receptor) agonist for male infertility and as an ovulation trigger.
  • Both candidates are orally dosed small molecules, positioned as a potential alternative to the injectable gonadotropins that currently dominate fertility treatment.
  • PostEra used its computational/AI discovery platform to design the molecules and to engineer around selectivity and liability issues; the startup had pivoted toward fertility and PMOS programs roughly a year earlier.
  • The transaction acquires specific programs rather than the whole company, following PostEra's 2025 C&EN "10 Startups to Watch" recognition.
💡 Points

Mid-double-digit millions for two programs, not a company, is the tell: EMD Serono is buying de-risked assets à la carte rather than paying PostEra's AI-platform premium, the same capital-efficient logic behind a growing wave of biopharma bolt-ons that skip a full acquisition. Fertility is a structurally underserved category: injectable gonadotropins have dominated IVF stimulation for decades with almost no oral competition, so a credible oral FSHR/LHCGR agonist pair is a genuine convenience-and-compliance wedge, not incremental pipeline filler. For PostEra, the more interesting signal is monetization strategy: an AI-native biotech cashing out individual de-risked programs rather than building toward its own pipeline or IPO. For Merck KGaA, it's a low-risk way to reload EMD Serono's fertility franchise with next-gen oral chemistry without integration risk.

Merck KGaA buys PostEra's oral fertility molecules ↗